

ARTICLE

Received 18 Jun 2013 | Accepted 20 Dec 2013 | Published 22 Jan 2014

DOI: 10.1038/ncomms4174

# Lysine-specific demethylase 1 regulates differentiation onset and migration of trophoblast stem cells

Dongmei Zhu<sup>1,\*</sup>, Stefanie Hölz<sup>1,\*</sup>, Eric Metzger<sup>1</sup>, Mihael Pavlovic<sup>2</sup>, Anett Jandausch<sup>1</sup>, Cordula Jilg<sup>1</sup>, Petra Galgoczy<sup>1</sup>, Corinna Herz<sup>1</sup>, Markus Moser<sup>3</sup>, Daniel Metzger<sup>4</sup>, Thomas Günther<sup>1</sup>, Sebastian J. Arnold<sup>2,5</sup> & Roland Schüle<sup>1,5</sup>

Propagation and differentiation of stem cell populations are tightly regulated to provide sufficient cell numbers for tissue formation while maintaining the stem cell pool. Embryonic parts of the mammalian placenta are generated from differentiating trophoblast stem cells (TSCs) invading the maternal decidua. Here we demonstrate that lysine-specific demethylase 1 (Lsd1) regulates differentiation onset of TSCs. Deletion of *Lsd1* in mice results in the reduction of TSC number, diminished formation of trophoblast tissues and early embryonic lethality. *Lsd1*-deficient TSCs display features of differentiation initiation, including alterations of cell morphology, and increased migration and invasion. We show that increased TSC motility is mediated by the premature expression of the transcription factor *Ovo2* that is directly repressed by *Lsd1* in undifferentiated cells. In summary, our data demonstrate that the epigenetic modifier *Lsd1* functions as a gatekeeper for the differentiation onset of TSCs, whereby differentiation-associated cell migration is controlled by the transcription factor *Ovo2*.

<sup>1</sup>Urologische Klinik und Zentrale Klinische Forschung, Klinikum der Universität Freiburg, Breisacher Strasse 66, 79106 Freiburg, Germany. <sup>2</sup>Medizinische Universitätsklinik, Abteilung Innere Medizin IV, Nephrologie, Klinikum der Universität Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany. <sup>3</sup>Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany. <sup>4</sup>Department of Physiological Genetics, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch 67404, France. <sup>5</sup>BIOS Centre of Biological Signalling Studies, Albert-Ludwigs-University, Freiburg, Germany. \* These authors contributed equally to this work. Correspondence and requests for materials should be addressed to T.G. (email: thomas.guenther@uniklinik-freiburg.de) or to S.J.A. (email: sebastian.arnold@uniklinik-freiburg.de) or to R.S. (email: roland.schuele@uniklinik-freiburg.de).

During mammalian preimplantation development, the first two types of precursor cells to form are the inner cell mass (ICM) and the trophoblast. The ICM further differentiates into primitive endoderm and the epiblast, the latter containing the progenitor cells that will form the embryo proper. Mural trophoblast cells that are not in direct contact with the ICM differentiate early to form primary trophoblast giant cells mediating implantation of the blastocyst into the uterine wall shortly after embryonic day 3.5 (E3.5). Polar trophoblast cells that directly overlie the ICM give rise to trophoblast stem cells (TSCs) that are the cellular source for the embryonic part of the placenta. TSCs retain the capacity to self-renew and maintain an undifferentiated state that we refer to as stemness state. From E5.5, TSCs are found in extraembryonic ectoderm and until E9.5 in the chorionic ectoderm. Propagation of TSCs depends on Tgf $\beta$  and Fgf signals provided by the underlying epiblast, which are further enhanced by activities of feed-forward regulatory loops in the TSC compartment that also act on the epiblast<sup>1</sup>. Thus, trophoblast and epiblast propagation depend on reciprocal tissue crosstalk<sup>2</sup>. The extraembryonic ectoderm and at later stages the chorionic ectoderm provide TSCs that constitute the ectoplacental cone<sup>3</sup>, which will ultimately give rise to cells of the different placental lineages, syncytiotrophoblast, spongiotrophoblast and secondary trophoblast giant cells<sup>2,3</sup>. Multipotency and stemness of TSCs are characterized by the expression of a set of stem cell-associated transcription factors including caudal type homeobox2 (Cdx2)<sup>4</sup> and eomesodermin (Eomes)<sup>5,6</sup>. Loss-of-function studies have demonstrated crucial requirements of both factors for maintenance of TSCs in an undifferentiated state and downregulation of Cdx2 and Eomes denotes the loss of stem cell state<sup>4–6</sup>. Furthermore, TSC differentiation is accompanied by changes in cellular behaviour, such as increased cell size and acquisition of migration and invasion capacities required to form the embryonic–maternal interface of the placenta<sup>7</sup>. To date, little is known about cell autonomous mechanisms that repress premature TSC differentiation and differentiation-associated changes in cell behaviour.

Recently, it became evident that chromatin-modifying enzymes function in tight cooperation with transcription factors to regulate stemness state and differentiation<sup>8</sup>. Epigenetic control mechanisms thus serve as an additional layer in the regulation of gene expression<sup>9–12</sup>. Acetylation, phosphorylation and methylation are reversible post-translational histone modifications. The methylation status of histone H3 at lysine 4 and 9 (H3K4 and H3K9, respectively) is linked to the expression level of the corresponding gene. While di- and trimethylated H3K4 (H3K4me3/2) are so-called ‘active chromatin marks’ associated with active transcription, di- and trimethylated H3K9 (H3K9me3/2) are denoted transcriptionally ‘repressive marks’<sup>9</sup>. We and others have shown that lysine-specific demethylase 1 (Lsd1; also known as Kdm1a, Aof2) selectively removes mono- and dimethyl groups from H3K4 or H3K9, thereby causing either repression or activation of gene transcription<sup>13–19</sup>.

Several studies have reported that *Lsd1*-deficient mouse embryos die prior to gastrulation at E7.5 (refs 19–22) proposing predominant functions in pluripotent cells of the epiblast. Analysis of *Lsd1*-deficient mouse embryonic stem cells in culture suggested a progressive loss of DNA methylation<sup>19</sup>, altered expression of genes crucial for ES cell differentiation<sup>21</sup> or a bias towards extraembryonic lineage differentiation<sup>20</sup>. Furthermore, Adamo *et al.*<sup>23</sup> reported that LSD1 regulates the balance between self-renewal and differentiation of human ESCs (hESCs). In contrast, analyses of Lsd1 functions in other stem cell compartments of the early embryo, including functional studies in TSCs, have remained elusive.


Here we analyse *Lsd1*-deficient pregastrulation-stage mouse embryos and observe previously unrecognized defects in the trophoblast lineage. The trophoblast-specific deletion of *Lsd1* leads to a significant reduction in the extraembryonic ectoderm, indicating an intrinsic requirements of Lsd1 function for trophoblast development. We define the transcription factor *ovol-like 2* (*Ovol2*) as a directly repressed Lsd1 target gene, thereby inhibiting premature cell migration and invasion. In conclusion, our data reveal that the epigenetic modifier Lsd1 acts as a crucial coordinator of trophoblast development by inhibiting premature differentiation onset accompanied with increased cell migration.

## Results

**Differential requirements of Lsd1.** Several studies have reported functions of Lsd1 in ESCs and in the early epiblast<sup>19–24</sup>. Whether or not absence of Lsd1 in the epiblast indeed accounts for the early embryonic lethality of *Lsd1*-deficient embryos preceding E7.5 has not been conclusively addressed. To specifically dissect Lsd1 functions in the different cell lineages of the pregastrulation stage mouse embryo, we engineered a novel conditional *Lsd1* allele by flanking exon 1 with loxP sites. In agreement with earlier reports<sup>19–22</sup>, ubiquitous deletion of the conditional *Lsd1* allele (*Lsd1*<sup>-/-</sup>) leads to early embryonic lethality, and only resorbed embryos are detected by E7.5 (Fig. 1a). To evaluate tissue-restricted functions, we deleted *Lsd1* by crossing the conditional *Lsd1* allele to the well-described transgenic *Sox2.Cre* deleter strain<sup>25</sup>, which robustly mediates Cre recombination specifically in the early post-implantation epiblast (*Lsd1*<sup>Sox2-Cre</sup>) but not in the extraembryonic lineages. Immunofluorescence staining confirms epiblast-specific deletion of Lsd1 while expression is maintained in other tissues, namely the visceral endoderm and the extraembryonic ectoderm (Fig. 1b). Unexpectedly, epiblast-specific deletion of *Lsd1* delays the early lethal phenotype of ubiquitous *Lsd1*<sup>-/-</sup> embryos (Fig. 1a), and *Lsd1*<sup>Sox2-Cre</sup> embryos appear grossly normal at E7.5. Further development of *Lsd1*<sup>Sox2-Cre</sup> embryos is arrested shortly after gastrulation onset and they do not undergo embryonic turning at E8.5. Besides the developmental block at later stages, our results demonstrate a remarkably normal development of *Lsd1*<sup>Sox2-Cre</sup> embryos until midgastrulation, suggesting additional functions of Lsd1 within the extraembryonic lineages. Consequently, we specifically deleted *Lsd1* in TSCs of the extraembryonic ectoderm using an *Eomes*<sup>Cre</sup> deleter strain (*Lsd1*<sup>Eomes-Cre</sup>)<sup>26</sup>, where Cre is active in TSCs from early post-implantation stages onwards (Fig. 1b). Mutant embryos develop beyond gastrulation (Fig. 1a,b) but show severe morphological abnormalities at E7.5 (Fig. 1a) with development arrest before E8.5.

Thus, in comparison to constitutive *Lsd1*-deficient embryos, specific deletion in either the epiblast or the trophoblast leads to less pronounced phenotypes demonstrating requirements of Lsd1 in both compartments for normal embryonic development.

**Deletion of Lsd1 impairs trophoblast development.** To further delineate functions of Lsd1 in the different tissues of the early embryo, we performed histological analysis of wild-type, *Lsd1*<sup>-/-</sup>, *Lsd1*<sup>Sox2-Cre</sup> and *Lsd1*<sup>Eomes-Cre</sup> embryos at E6.5 (Fig. 1b for schematic of the different embryonic cell types). Consistent with previous reports<sup>19–22</sup>, we find that *Lsd1*<sup>-/-</sup> embryos are significantly reduced in size but possess cells of the three early embryonic lineages, namely epiblast, extraembryonic ectoderm and primitive endoderm/visceral endoderm as shown by haematoxylin and eosin (HE) staining (Fig. 1b). Accordingly, immunofluorescence analysis shows similar expression of the pluripotency-associated marker Oct4 (also known as Pou5f1)<sup>27</sup> in



**Figure 1 | *Lsd1*<sup>-/-</sup> embryos and trophoblast-specific deletion of *Lsd1* exhibit pronounced trophoblast defects. (a)** Representative morphology of whole-mount wild-type (WT), constitutively deleted (*Lsd1*<sup>-/-</sup>), epiblast-specific (*Lsd1*<sup>Sox2-Cre</sup>) and trophoblast-specific *Lsd1*-deficient (*Lsd1*<sup>Eomes-Cre</sup>) embryos at E7.5. **(b)** Comparison of histological sections of WT, *Lsd1*<sup>-/-</sup>, *Lsd1*<sup>Sox2-Cre</sup> and *Lsd1*<sup>Eomes-Cre</sup> E6.5 embryos by HE staining, immunofluorescence with indicated antibodies and the corresponding IgG controls. Dashed lines circle the *Lsd1*-deficient parts of the embryos. Arrows indicate ectopic, Eomes-positive cells outside of the region of the extraembryonic ectoderm. The cartoon is depicting the different cell lineages of the E6.5 embryo. Scale bars represent 200 μm **(a)** and 100 μm **(b)**.

the epiblast of wild-type and *Lsd1*<sup>-/-</sup> embryos (Fig. 1b; Supplementary Fig. 1a). To reveal the presence of trophoctoderm and visceral endoderm, we used antibody staining for *Eomes*, which is a marker for TSCs and embryonic visceral endoderm cells<sup>28</sup>. Expression of *Oct4* and *Eomes* indicates the presence of all three lineages in *Lsd1*<sup>-/-</sup> embryos; however, in comparison to wild-type embryos we observed a striking reduction of *Eomes*- and *Cdx2*-positive TSCs in the extraembryonic ectoderm (Fig. 1b; Supplementary Fig. 1a,b).

To analyse whether the reduced number of *Eomes*-expressing TSCs is a secondary effect due to the loss of *Lsd1* in the epiblast, or whether this resembles an autonomous effect of *Lsd1* depletion in the trophoctoderm, we analysed *Lsd1*<sup>Sox2-Cre</sup> and *Lsd1*<sup>Eomes-Cre</sup> embryos. While deletion of *Lsd1* from the epiblast (*Lsd1*<sup>Sox2-Cre</sup>) does not compromise the trophoctoderm compartment, deletion of *Lsd1* in the trophoctoderm (*Lsd1*<sup>Eomes-Cre</sup>) leads to a markedly reduced size of the extraembryonic ectoderm, similar to the constitutive *Lsd1*<sup>-/-</sup> mutant embryos (Fig. 1b). Interestingly, we consistently observed ectopic, *Eomes*-expressing cells that were detached from the extraembryonic ectoderm and showed enlarged cell size in *Lsd1*<sup>-/-</sup> embryos. These types of cells could also be found in *Lsd1*<sup>Eomes-Cre</sup> trophoctoderm-specific mutants, albeit at reduced frequency, whereas similar observations were not made in wild-type or *Lsd1*<sup>Sox2-Cre</sup> embryos (Fig. 1b).


**Lsd1 regulates differentiation of TSCs.** TSCs can be efficiently differentiated into derivatives of the trophoctoderm, namely syncytiotrophoblast, spongiotrophoblast and trophoblast giant cells in culture<sup>2</sup>. To test for the differentiation potential of *Lsd1*<sup>-/-</sup> TSCs, we used a cell culture system as the corresponding *in vitro* correlate<sup>29</sup>. TSCs were isolated from E3.5 blastocysts harbouring either a transgenic doxycyclin (Dox)-inducible RNA interference construct (*Lsd1* *iKD*) or the tamoxifen (Tx)-inducible CreER<sup>T2</sup>-recombinase combined with the *Lsd1* conditional alleles to inducibly delete *Lsd1* (*Lsd1* *iKO*). Drug administration leads to the loss of *Lsd1* protein by day 8 in *iKO* and day 4 in *iKD* cells as shown using western blot analyses (Fig. 2a). Of note, all experiments were performed with several independent *iKD* and *iKO* TSCs excluding that clonal variations account for observed phenotypes. For simplicity, only data from *iKO* cells are shown in following analyses, if not otherwise indicated. We first treated *Lsd1* *iKO* cells for 8 days with Tx prior to induction of differentiation by the removal of FGF4 and mouse embryonic fibroblast (MEF)-conditioned medium. As expected, differentiation leads to rapid downregulation of TSC stemness marker genes such as *Cdx2* and *Eomes* in both *Lsd1*<sup>-/-</sup> and wild-type control cells (Fig. 2b). Concomitantly, marker genes for differentiating trophoctoderm become upregulated from day 2 of differentiation (Fig. 2b). Interestingly, the differentiation behaviour of wild-type and *Lsd1*<sup>-/-</sup> cells exhibits striking differences. While *Lsd1*<sup>-/-</sup> cells show a significant increase in expression of the syncytiotrophoblast marker *Gcm1*, spongiotrophoblast markers *Mash2* and *Tpbpa* are significantly reduced compared with the wild type (Fig. 2b). Similarly, the trophoblast giant cell markers *Pl1*, *Pl2* (also known as *Pr3d1* and *Pr3b1*, respectively) and *Plf* (also known as *Pr2c2*) are drastically reduced or absent in *Lsd1*<sup>-/-</sup> cells while they become abundantly expressed in differentiating *Lsd1*-proficient TSCs (Fig. 2b; Supplementary Fig. 2a,b). Of note, Tx treatment does not alter the differentiation behaviour of wild-type TSCs (Supplementary Fig. 2c). We therefore conclude that the loss of *Lsd1* impairs differentiation towards spongiotrophoblast and secondary giant cells in favour of syncytiotrophoblast.

To further confirm requirements of *Lsd1* for TSC differentiation, we reintroduced *Lsd1* into *Lsd1* *iKO* TSCs and examined the expression of stem cell and differentiation markers in the absence or presence of Tx. As expected, expression levels of the stem cell markers *Cdx2* and *Eomes* are not significantly affected, while transcription of the syncytiotrophoblast, spongiotrophoblast and giant cell marker genes *Pl1*, *Tpbpa*, *Plf* and *Gcm1*, respectively, are restored to wild-type levels, demonstrating that the phenotype of *Lsd1*<sup>-/-</sup> cells can be rescued by ectopic expression of *Lsd1* (Fig. 2c; Supplementary Fig. 2d,e). Next, we addressed whether the demethylase activity of *Lsd1* is required for directing TSC fate by ectopic expression of a catalytic inactive mutant of *Lsd1* (*Lsd1*<sup>Mut</sup>)<sup>30</sup>. Ectopic expression of the *Lsd1* mutant protein in *Lsd1*<sup>-/-</sup> TSCs does not alter the transcription of stem cell-associated genes such as *Eomes* (Supplementary Fig. 2d). Unlike wild-type *Lsd1*, the enzymatic inactive protein fails to restore the transcription of trophoblast differentiation markers such as *Plf* to wild-type levels (Supplementary Fig. 2d). We therefore conclude that the enzymatic activity of *Lsd1* plays a decisive role in controlling the lineage decisions of differentiating TSCs.

To quantitatively assess whether there are differences in the proliferation of wild-type and *Lsd1*<sup>-/-</sup> TSCs, we performed BrdU incorporation assays. Under stemness-maintaining conditions, *Lsd1*-proficient and *Lsd1*-deficient cells do not show significant differences in proliferation (Fig. 2d). However, when TSCs are induced to differentiate, we observe significantly reduced proliferation rates of *Lsd1*<sup>-/-</sup> cells (Fig. 2d). To distinguish between endoreduplication of trophoblast giant cells and cell proliferation, we performed a second DNA content-independent assay. Determination of the cell number by FACS before and during differentiation corroborated the decrease in proliferation specifically in differentiating *Lsd1*-deficient TSCs (Fig. 2d). The reduced proliferation of differentiated *Lsd1*<sup>-/-</sup> TSCs may account, at least in part, for the overall decrease in trophoctoderm tissue in *Lsd1*<sup>-/-</sup> embryos.


**Lsd1 restrains migration and invasion of TSCs.** The analysis of cell morphology and cellular behaviour revealed striking changes in both *iKO* and *iKD* *Lsd1*-depleted TSCs in comparison to control cultures (Fig. 3). Typically, wild-type undifferentiated TSCs are characterized by the formation of dense epithelial colonies with hardly visible cell borders and relatively small cell size. In contrast, upon depletion of *Lsd1*, the cell size of TSCs is markedly increased, and the morphology of the colonies is less compact with clearly discernable cell borders (Fig. 3a). These features are usually associated with the early onset of TSC differentiation (Day 2; Fig. 3a). FACS-assisted cell size analyses revealed enlargement of *Lsd1*<sup>-/-</sup> TSCs similar to the size increase of wild-type TSCs on day 2 of differentiation (Fig. 3b). Additionally, phalloidin staining of the cytoskeleton reveals increased spreading of *Lsd1*<sup>-/-</sup>-TSCs (Supplementary Fig. 3a). However, despite the fact that *Lsd1*<sup>-/-</sup> TSCs lose their characteristic morphology, they maintain expression of stemness-associated markers *Cdx2* and *Eomes* (Fig. 2b).

To explore whether the change in cell morphology of *Lsd1*-deficient TSCs is reflected by functional differences in cell behaviour, we performed migration and invasion assays using a transwell system in real time. TSCs were either kept under stemness conditions or induced to differentiate during the course of the experiment. Interestingly, *Lsd1*<sup>-/-</sup> TSCs maintained under stemness conditions already show a significant increase in cell migration (Fig. 3c) and invasion (Fig. 3d), which is further enhanced under differentiation conditions (Fig. 3c,d). To control for specificity, we treated *Lsd1*-proficient wild-type TSCs with Tx, which does not alter migration (Supplementary Fig. 3b).



**Figure 2 | *Lsd1* regulates differentiation of TSCs.** (a) Efficiency of *Lsd1* knockdown (*Lsd1 iKD*) and Cre-mediated genetic deletion (*Lsd1 iKO*) in TSCs is analysed using western blot. Cells were treated with Dox or Tx for the indicated duration. Specificity of *Lsd1* knockdown is verified using TSCs expressing short hairpin RNA directed against LacZ (*Ctrl iKD*). Tubulin is used as a loading control. (b) qRT-PCR analyses of mRNA expression levels of *Lsd1* and indicated lineage markers during differentiation in *Lsd1 iKO* TSCs in the absence or presence of Tx. (c) The expression levels of indicated genes in *iKO* TSCs transfected with an *Lsd1*-expression vector (*Lsd1*), or an empty vector (Ctrl) is monitored during differentiation by qRT-PCR in the absence or presence of Tx. (d) Proliferation assays of *Lsd1 iKO* TSCs in stemness and differentiation (Diff) conditions in the absence or presence of Tx determined by BrdU incorporation (upper panel) or by cell number using FACS (lower panel). qRT-PCR data are normalized to *Gapdh* and represented as mean + s.e.m. Experiments (b-d) were independently repeated at least three times in triplicate. Statistical analysis was performed using two-tailed Student's t-test. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .






**Figure 3 | *Lsd1* restrains migration and invasion of TSCs.** (a) Representative images of TSC colonies showing the morphology of WT, *Lsd1 iKO*, *Ctrl iKD* and *Lsd1 iKD* TSCs after administration of Tx or Dox for 8 days in stemness conditions in comparison to WT TSCs after 2 days of differentiation. Scale bars represent 100  $\mu$ m. (b) FACS analyses of cell size of wild-type TSCs on day 0 (green), day 2 (blue) and *Lsd1<sup>-/-</sup>* TSCs (red). (c) Migration assays of *Lsd1 iKO* TSCs in the absence or presence of Tx under stemness or differentiation (Diff) conditions recorded in real time. Depletion of *Lsd1* in *iKO* cells is controlled using western blot. Tubulin is used as a loading control. (d) 3D-matrix invasion assays of *Lsd1 iKO* TSCs in the absence or presence of Tx under stemness or differentiation (Diff) conditions recorded in real time. Cells that invaded the matrix and reached the lower surface of the transwell filter are stained by crystal violet. Scale bars represent 3 mm. (e) Migration assays of undifferentiated *Lsd1 iKO* TSCs transfected with an *Lsd1*-expression plasmid (*Lsd1*) or an empty vector (Ctrl) in the absence or presence of Tx demonstrate that *Lsd1* expression rescues increased migration of *Lsd1 iKO* cells. Bars represent mean  $\pm$  s.e.m. or + s.e.m. Experiments (c–e) were independently repeated at least three times in triplicate. Statistical analysis was performed using two-tailed Student's *t*-test. \*\**P* < 0.01; \*\*\**P* < 0.001.

Importantly, reintroducing *Lsd1* rescues the elevated migration of *Lsd1*<sup>-/-</sup> TSCs (Fig. 3e). To determine whether the demethylase activity of *Lsd1* accounts for the observed migration phenotype, we additionally performed migration analysis of wild-type TSC in the presence of specific *Lsd1* inhibitors<sup>31,32</sup>. Similar to the deletion of *Lsd1*, inhibitor treatment causes a significant increase in TSC migration indicating that the enzymatic activity of *Lsd1* is essential (Supplementary Fig. 3c). In agreement, the introduction of an enzymatic inactive *Lsd1* mutant does not rescue the migration phenotype of *Lsd1*<sup>-/-</sup> TSCs (Supplementary Fig. 3d). Thus, the epigenetic regulator *Lsd1* represses the migration of TSCs in culture, potentially also explaining the appearance of *Eomes*-expressing trophoblast cells outside the extraembryonic ectoderm in *Lsd1*-deficient embryos.

**Deletion of *Lsd1* lowers the threshold for differentiation onset.**

To identify potential *Lsd1* target genes that have an impact on the behavioural changes of *Lsd1*-depleted TSCs, we performed

transcriptional profiling by microarrays in the presence or absence of *Lsd1*. RNA was collected on day 0 (TSCs under stemness conditions), day 2 and day 4 after induction of differentiation. We first analysed *Lsd1*-dependent gene expression by comparison of transcription in *Lsd1*-proficient and *Lsd1*<sup>-/-</sup> TSCs at all three time points. In total, the expression of ~1,000 genes is altered (analysis of variance test, *P*-value < 10<sup>-5</sup> and more than twofold expression change) (Fig. 4a). In the absence of *Lsd1*, roughly 700 genes show increased expression while the transcription of 300 genes is decreased, demonstrating that the majority of target genes is repressed by *Lsd1*. Analyses of gene ontology and signalling pathways did not reveal any significant signature (Supplementary Tables 1,2). Based on our previous results, we hypothesized that *Lsd1* depletion under stemness conditions alters the characteristics of TSCs towards an early-onset-differentiated phenotype. Therefore, we compared the gene expression profiles during differentiation (wild-type TSCs day 0 versus day 2 of differentiation) with the differentially expressed genes after *Lsd1* deletion (*Lsd1*<sup>-/-</sup> TSCs versus wild-type TSCs



**Figure 4 | Premature differential expression of differentiation-associated genes in *Lsd1*-deficient TSCs.** (a) Comparative expression heat map of WT and *Lsd1* iKO TSCs under stemness and differentiation conditions shows all significantly *Lsd1*-regulated genes. (b) Venn diagrams showing the overlap of differentially expressed genes in WT and *Lsd1* iKO TSCs under stemness conditions (purple) and genes that are differentially expressed in WT TSCs after 2 (bright green) and 4 (dark green) days of differentiation. (c) Comparison of mRNA and protein expression levels of *Lsd1* and the stemness markers *Cdx2* and *Eomes* by qRT-PCR and western blot in *Lsd1* iKD and *Lsd1* iKO TSCs treated with Dox or Tx for the indicated time points. Wild-type TSCs induced to differentiate for 4 days are used as differentiation (Diff) control and tubulin as loading control. (d) qRT-PCR analyses of mRNA expression levels of *Lsd1* and indicated lineage markers during early time points of differentiation in *Lsd1* iKO TSCs in the absence or presence of Tx. qRT-PCR data are normalized to *Gapdh* and represented as mean + s.e.m. Experiments (c,d) were independently repeated at least three times in triplicate. Statistical analysis was performed using analysis of variance (a) and two-tailed Student's *t*-test (b-d). \*\*\**P* < 0.001.

under stemness conditions; Supplementary Table 3). Importantly, 52 genes associated with the differentiation of wild-type TSCs between day 0 and day 2 are already prematurely differentially expressed in *Lsd1*<sup>-/-</sup> cells under stemness-maintaining conditions (day 0; Fig. 4b). This group comprises 26% (52 of 198) of all genes regulated by *Lsd1* under stemness conditions. This proportion increases to 39% (78 of 198) when those genes are compared that are differentially regulated during TSC differentiation between day 0 and day 4 (Fig. 4b).


The altered expression of genes associated with early differentiation confirmed our hypothesis that *Lsd1*<sup>-/-</sup> TSCs lose stem cell characteristics. However, under stemness-maintaining conditions, *Cdx2* and *Eomes* expression is similar in *Lsd1*-depleted and *Lsd1*-proficient TSCs (Fig. 4c). This raises the question whether *Lsd1*<sup>-/-</sup> TSCs might initiate the differentiation onset faster than wild-type cells upon removal of stem cell-maintaining conditions. To validate this hypothesis, we quantified the transcription of TSC marker genes during the first hours of differentiation. Upon induction of differentiation, the transcription of both stem cell marker genes is reduced considerably faster in *Lsd1*-deficient TSCs implying that the deletion of *Lsd1* lowers the threshold for differentiation onset (Fig. 4d). The fact that *Lsd1*-depleted TSCs show characteristics of early differentiation (Figs 3 and 4d) suggests that the group of prematurely differentially expressed genes in *Lsd1*<sup>-/-</sup> cells contains *Lsd1* targets that have an impact on cellular morphology and behaviour such as migration.

### **Lsd1 controls expression of *Ovol2* in TSCs and trophoblast.**

Next, we aimed to identify *Lsd1*-regulated genes that mediate the effect of *Lsd1* depletion on increased TSC migration. First, we validated our microarray analysis via quantitative reverse transcription-PCR (qRT-PCR) by choosing *Lsd1* and known markers of trophoblast stemness and differentiation such as *Cdx2* and *Pl1* and *Pl2*, in addition to selected differentially expressed genes (Fig. 2b; Supplementary Fig. 2a). From our list of confirmed differentially expressed genes (Supplementary Fig. 4), we consequently focused on genes with potential functions in cell migration. Combining data of our expression profiles with published expression patterns and reports on gene-function, we identified the zinc-finger transcription factor *Ovol2* as a promising candidate. *Ovol2* expression is first found in cells of the chorionic plate and later within the labyrinthine layer of the developing placenta<sup>33</sup>. Targeted deletion of *Ovol2* leads to embryonic death from E9.5 with a pronounced phenotype of the placenta, characterized by a lack of an elaborated labyrinthine layer<sup>33</sup>. Furthermore, it was suggested that *Ovol2* is involved in the migration of neural crest derivatives<sup>34</sup>.

Using qRT-PCR, western blot analyses and a polymerase II chromatin immunoprecipitation (ChIP) we confirmed the dynamic expression of *Ovol2* during TSC differentiation (Fig. 5a,b; Supplementary Fig. 5a). While *Ovol2* expression is low in *Lsd1*-proficient TSCs under stemness conditions, there is a continuous and robust increase in expression during TSC differentiation. In *Lsd1*<sup>-/-</sup> TSCs, the expression of *Ovol2* is prematurely increased under stemness conditions and during early stages of differentiation, while the differences in RNA and protein levels between control and *Lsd1*-deficient TSCs equal during late differentiation (Fig. 5a,b). Re-introduction of *Lsd1* in *Lsd1*<sup>-/-</sup> TSCs restored *Ovol2* transcription and protein levels (Supplementary Fig. 5b).

To assess whether *Ovol2* expression is similarly changed *in vivo* in *Lsd1*-deficient trophoblast, we performed *in situ* hybridization analysis of histological sections from wild-type, *Lsd1*<sup>-/-</sup> and *Lsd1*<sup>Eomes-Cre</sup> embryos at E6.5. In wild-type




**Figure 5 | *Lsd1* represses expression of *Ovol2* in TSCs and in the trophoblast. (a)** qRT-PCR analyses of mRNA expression levels of *Ovol2* during differentiation of *Lsd1* iKO TSCs in the absence or presence of Tx. **(b)** Western blot analyses of *Lsd1* and *Ovol2* protein levels in *Lsd1* iKO TSCs on days 0 and 4 of differentiation in the presence or absence of Tx. Beta actin is used as loading control. **(c)** *In situ* hybridization using an *Ovol2* probe at E6.5 in WT, *Lsd1*<sup>-/-</sup> and *Lsd1*<sup>Eomes-Cre</sup> embryos. Arrows indicate ectopic *Ovol2* expression. Scale bars represent 100  $\mu$ m. qRT-PCR data are normalized to *Gapdh* and are represented as mean + s.e.m. Experiment (a) was independently repeated at least three times in triplicate. Statistical analysis was performed using two-tailed Student's *t*-test. \**P* < 0.05; \*\*\**P* < 0.001.

embryos, *Ovol2* is expressed in syncytiotrophoblast cell from E8 (Supplementary Fig. 5c) with no *Ovol2* expression in embryonic or extraembryonic regions of the wild-type conceptus at E6.5 (Fig. 5c). In striking contrast, we find abundant expression of *Ovol2* within the extraembryonic compartments of *Lsd1*<sup>-/-</sup> and of *Lsd1*<sup>Eomes-Cre</sup> embryos prematurely at E6.5 (Fig. 5c). Thus, deletion of *Lsd1* leads to premature expression of *Ovol2* in cultured TSCs and in embryos.



**Lsd1 directly suppresses *Ovol2* expression in TSCs.** To investigate whether Lsd1 directly regulates and occupies the *Ovol2* promoter, we performed ChIP using an Lsd1-specific antibody followed by qPCR for genomic regions of the *Ovol2* gene locus. Lsd1 specifically binds to a distal promoter region 1.3 kb upstream of the transcription start site (TSS) and around the TSS of the *Ovol2* gene (Fig. 6a; Supplementary Fig. 6a). Binding of Lsd1 is specific since using an IgG control or performing ChIP in

*Lsd1*<sup>-/-</sup> cells fails to enrich chromatin (Fig. 6; Supplementary Fig. 6a). To further control for specificity we analysed an unrelated region 4.6 kb upstream of the TSS that is not occupied by Lsd1 (Fig. 6a; Supplementary Fig. 6a,c). To analyse whether Lsd1 represses *Ovol2* transcription by the removal of mono- and dimethyl H3K4 marks at the *Ovol2* promoter, we performed ChIP with methyl-specific antibodies and compared the methylation levels of wild-type and *Lsd1*<sup>-/-</sup> TSCs. Consistent with increased



**Figure 6 | Lsd1 directly regulates *Ovol2* transcription in undifferentiated TSCs.** (a) ChIP experiments are performed with Lsd1 antibodies and IgG to detect Lsd1-specific binding at the distal promoter region ( $-1,437$  bp /  $-1,145$  bp) and the transcription start site ( $-38$  bp /  $+137$  bp) of *Ovol2* compared with a control region ( $-4,706$  bp /  $-4,567$  bp). (b) ChIP experiments are performed with the indicated antibodies to detect associated changes of chromatin marks at the *Ovol2* promoter ( $-1,437$  bp /  $-1,146$  bp). ChIP is performed using *Lsd1* iKO TSCs in the presence or absence of Tx under stemness conditions and after 4 days of differentiation. Bars are represented as mean + s.e.m. Experiments were independently repeated at least three times in triplicate. Statistical analysis was performed using two-tailed Student's *t*-test. \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .

*Ovol2* expression in *Lsd1*<sup>-/-</sup> TSCs (Fig. 5a,b; Supplementary Fig. 5a), levels of H3K4 methyl marks are increased in *Lsd1*<sup>-/-</sup> TSCs (Fig. 6b; Supplementary Fig. 6b,d) suggesting that *Lsd1* demethylates H3K4me2/1. Interestingly, H3K9 methylation levels are generally low at the *Ovol2* promoter and during TSC differentiation the overall amount of H3K4me3 does not increase (Fig. 6b; Supplementary Fig. 6b,d), indicating that additional chromatin modifiers might contribute to the transcriptional regulation of *Ovol2*. Consistent with this hypothesis we observe a decrease in the repressive H3K27me3 mark at the *Ovol2* promoter during differentiation (Fig. 6b; Supplementary Fig. 6b). Importantly, on day 4 of TSC differentiation, *Lsd1* does no longer bind to the *Ovol2* promoter (Fig. 6b), despite abundant expression of *Lsd1* throughout differentiation (Fig. 2b; Supplementary Fig. 2b,c). Consequently, no significant differences in the levels of methylated H3K4 and H3K9 between *Lsd1*-proficient and *Lsd1*<sup>-/-</sup> TSCs are detected during differentiation (Fig. 6b; Supplementary Fig. 6b). In summary, our data suggest that *Lsd1* represses *Ovol2* expression in undifferentiated TSCs by binding to its promoter. In contrast, in differentiating TSCs *Lsd1* is not associated with the promoter and consequently does no longer prevent *Ovol2* expression, despite persistent *Lsd1* protein levels.

**Ovol2 induces migration and invasion of *Lsd1*<sup>-/-</sup> TSCs.** Since we observe increased and aberrant migration and invasion of *Lsd1*-deficient TSCs, we asked whether prematurely expressed *Ovol2* accounts for the pro-migratory phenotype. We ectopically expressed *Ovol2* in wild-type TSCs and measured migration and invasion in real time. Intriguingly, *Ovol2* overexpression induces increased TSC migration (Fig. 7a) and invasion (Fig. 7b) and thus strikingly phenocopies the behaviour of *Lsd1*<sup>-/-</sup> TSCs. To address whether *Ovol2* is the predominant factor that mediates the loss of *Lsd1* phenotype, we performed miRNA-mediated knockdown of *Ovol2* in *Lsd1*<sup>-/-</sup> TSCs. Remarkably, knockdown of *Ovol2* completely rescues the enhanced migratory phenotype caused by the deletion of *Lsd1* (Fig. 7c). Accordingly, knockdown of *Ovol2* in wild-type cells decreases migration specifically in differentiating TSCs, while knockdown of *Ovol2* in undifferentiated TSCs, which hardly express *Ovol2* (Fig. 5a,b), does not affect migration (Fig. 7d). Of note, knockdown of *Ovol2* does not increase *Lsd1* expression (Fig. 7c), demonstrating that *Ovol2* is a major mediator of *Lsd1*-controlled migration. Importantly, the ectopic expression of *Ovol2* does not affect stemness and differentiation of TSCs indicated by unaltered *Cdx2*, *Pl1* and *Gcm1* expression levels, respectively (Supplementary Fig. 7). Taken together, our data demonstrate that enhanced and premature expression of *Ovol2* induced by functional loss of *Lsd1* accounts for the pro-migratory phenotype observed in *Lsd1*<sup>-/-</sup> TSCs.

## Discussion

In the present study, we analyse functions of the histone demethylase *Lsd1* in the trophoblast and identify *Lsd1* as an important regulator for differentiation onset in TSCs. In the absence of *Lsd1*, TSCs exhibit several features of early differentiating trophoblast cells such as increased cell size, differentiation-associated changes in the gene-expression signature, and onset of cell migration and invasion. Interestingly, the premature expression of a gene signature characterizing early differentiation is not associated with the general downregulation of stemness-maintaining transcription factors such as *Cdx2* and *Eomes*, and *Lsd1*-deficient TSCs can be maintained in culture over extended periods of time. This function of *Lsd1* is reminiscent to a previous report describing that *Lsd1* is required for the maintenance of pluripotency in hESCs by controlling the


bivalent chromatin marks at regulatory sites of early differentiation-associated genes<sup>23</sup>. Expression of endogenous *Lsd1* decreases during hESC differentiation. Accordingly, the loss of *Lsd1* in hESCs results in precocious differentiation onset. In comparison, deletion of *Lsd1* in mouse ESCs does not cause premature differentiation<sup>21,24</sup> and unlike the situation in hESCs, we do not find significant changes in the expression levels of endogenous *Lsd1* during the differentiation process of TSCs. One report showed that *Lsd1* is required for full silencing of the stem cell programme<sup>24</sup>, and Foster *et al.*<sup>21</sup> proposed that *Lsd1* is essential for the expression and appropriate timing of the key developmental regulators. Considering the role of *Lsd1* in TSCs, it is tempting to speculate that the enzymatic activity of *Lsd1* might generally act in stem cell populations to control the timely transition from stemness state to differentiation. Since the levels of *Lsd1* are not altered during differentiation, *Lsd1* activity might be regulated either by post-translational modifications and/or by the composition of *Lsd1*-interacting proteins.

One prominent feature of differentiating TSCs is an increase in their migration and invasive behaviour. In our attempts to identify *Lsd1*-regulated genes that account for this pro-migratory behaviour, we found that premature expression of the direct target gene *Ovol2*, in major parts, mediates increased migration and invasiveness of *Lsd1*-deficient TSCs.

During migration of *Lsd1*<sup>-/-</sup> TSCs we observe reduced membrane staining for E-cadherin (*Cdh1*) and beta catenin (*Cttnb1*), required for the formation of epithelial cell–cell adherens junctions, and increased levels of the mesenchymal marker vimentin (*Vim*), two hallmarks of epithelial–mesenchymal transition (EMT) (Supplementary Fig. 3a). In contrast to our expectation, the genome-wide expression profiling did not reveal significant changes in the majority of the typical EMT-associated regulators such as *Snail*, *Twist1* or *Zeb1* in *Lsd1*<sup>-/-</sup> TSCs (Supplementary Table 4). Thus, our data currently do not allow to unequivocally classify the aberrant migration of *Lsd1*-deficient TSCs as EMT at the molecular level. Instead, we propose that *Ovol2* acts as a previously unrecognized inducer of migration and cell invasion during development. Indeed, the loss-of-function phenotype of *Ovol2*-deficient embryos reported by Unezaki *et al.*<sup>33</sup> already suggested that *Ovol2* is required for the invasive cell behaviour of developing blood vessels and expansion of the labyrinthine layer of the placenta, leading to embryonic death around E10.5. Importantly, in our experiments *Ovol2* does not seem to primarily have an impact on lineage specification of differentiating TSCs (Supplementary Fig. 7) but mostly affects cellular behaviour.

Interestingly, a recent study by Abbell *et al.*<sup>35</sup> reported on a similar migration phenotype of TSCs deficient for the protein kinase *Map3k4* and the histone acetyltransferase *CBP/p300*. These mutant TSCs concomitantly maintain properties of stemness state while showing increased migration and as such resemble features of *Lsd1*-deficient TSCs<sup>35</sup>. *Map3k4*-deficient TSCs exhibit a global absence of the H2AK5ac mark, a reduction of the H2BK5ac mark and an increase in H3K9ac in comparison with wild-type cells<sup>35</sup>. We compared the global levels of histone acetylation in wild-type and *Lsd1*<sup>-/-</sup> TSCs and found an increase in H2AK5ac and H2BK5ac marks, while the levels of H3K9ac were not altered (Supplementary Fig. 8a). Additionally, the data presented by Abbell *et al.*<sup>35</sup> reveal that neither *Lsd1* nor *Ovol2* are targets of *Map3k4* and *CBP/p300*, suggesting that distinct molecular pathways regulate migration during TSC differentiation.

Previous reports linked *Lsd1* with NuRD and CoREST complex to regulate EMT-related processes in cancer progression and in cell culture-based EMT assays<sup>17,36–38</sup>. More specifically, Wang *et al.*<sup>17</sup> showed that LSD1 influences the metastatic potential of breast cancer cell line MDA-MB-231. Expression profiling data



**Figure 7 | *Ovol2* expression mediates increased migration and invasion of *Lsd1*-depleted TSCs.** (a,b) Ectopically expressed *Ovol2* induces increased migration (a) and invasion (b) behaviour of undifferentiated TSCs, in comparison to control-transfected (Ctrl) TSCs as monitored in real time. Ectopic expression of V5-tagged *Ovol2* is controlled using western blot analysis. (c) Migration assays of undifferentiated *Lsd1* iKO TSCs in the absence or presence of Tx and simultaneous miRNA-mediated knockdown demonstrate decreased migration of *Lsd1*-depleted TSCs upon *Ovol2* depletion. mRNA expression levels of *Ovol2* and *Lsd1* were controlled with qRT-PCR. (d) Migration assays of undifferentiated and differentiating *Lsd1*-proficient TSCs upon *Ovol2* depletion in comparison to control (Ctrl) TSCs. qRT-PCR data are normalized to *Gapdh* and represented as mean + s.e.m. Bars represent mean ± s.e.m. or + s.e.m. Experiments were independently repeated at least three times in triplicate. Statistical analysis was performed using two-tailed Student's *t*-test. \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001.

from this report and our data show that *OVOL2* expression is not altered after the knockdown of *LSD1* in the MDA-MB-23 cell line (Supplementary Fig. 8b), indicating that *Lsd1* controls cell migration via different, cell-context-dependent mechanisms.

Interestingly, *Lsd1* not only controls differentiation onset of TSCs, but also directs TSC fate. *Lsd1* is required for the correct differentiation of spongiotrophoblast and trophoblast giant cells, while syncytiotrophoblast differentiation is promoted in the absence of *Lsd1*. This fits well to the observation of increased *Ovol2* levels found in the syncytiotrophoblast of the developing placenta. It will be interesting to learn which *Lsd1*-regulated genes control additional aspects of early TSC differentiation, including lineage specification and proliferation control.

As the most prominent feature of the *Lsd1* phenotype in the early embryo, we observed a drastic reduction in the extraembryonic ectoderm and its derivatives. This reduction in placental tissues could be caused either by reduced proliferation, increased cell death or premature differentiation. Surprisingly, *Lsd1*-deficient TSCs cultured in stemness-maintaining conditions do not show reduced proliferation and we could not observe increased cell death in the embryo. However, after differentiation onset, *Lsd1*-deficient cells show significantly reduced proliferation, possibly explaining the gross reduction in placental tissues outside of the extraembryonic ectoderm. Additionally, we cannot rule out that *Lsd1*-deficient TSCs in the embryo start to prematurely differentiate, even though *Lsd1*<sup>-/-</sup> TSCs can be maintained indefinitely under culture conditions. Under these culture conditions, the deletion of *Lsd1* does not seem to affect responsiveness to either signals of FGF or TGF $\beta$ , as demonstrated using western blot for the activated signalling mediators p-ERK and SMAD2 (Supplementary Fig. 8c) and maintained expression of TSC markers *Cdx2* and *Eomes*, which depend on Fgf and TGF $\beta$  signals.

In summary, our functional analyses of the epigenetic regulator *Lsd1* in TSCs during early stages of mouse development and in cell culture demonstrate that *Lsd1* is essential for trophoblast development by prevention of premature TSC differentiation onset including an increase in cell migration and invasion behaviour. Additionally, *Lsd1* is required for directing the fate of differentiating TSCs. Thus, this study contributes to the general understanding of epigenetic modulators and their importance for the initial steps of differentiation onset and differentiation-associated cell behaviour of stem cell populations.

## Methods

**Mice.** All mice were housed in the pathogen-free barrier facility of the University Medical Center Freiburg in accordance with the institutional guidelines and approved by the regional board. The targeting strategy for the conditional deletion of the first exon of *Lsd1* (*Lsd1*<sup>tm1Schüle</sup>) and the generation of Ppm1a<sup>creERT2</sup> mice is available upon request. *Tg(Sox2-cre)1Amc* and *Eomes*<sup>tm3.1(cre)Rob</sup> mice were previously described<sup>25,26</sup> and inducible *Lsd1* *iKD* mice were generated by introduction of the knockdown construct into the *Rosa26* locus via recombinase-mediated cassette exchange<sup>39</sup>. The following sequences were used to knockdown *Lsd1* (5'-TCCCGGATGTCACACTTCTGGAAAGCTTCAAGAGAGCTTCCAGAAAGTG TGACATCCTTTTAA-3'; 5'-CCTACAGTGTGAGACCTCGAAGTCTCTCGA AGGTCTTCACTGTAGGAAAAATGCGC-3'). Mice were genotyped with conventional PCR using standard conditions and primers listed in Supplementary Table 5.

**TSC cell culture.** Derivation and cultures of TSCs was performed according to published protocols<sup>29</sup>. In short, primary TSC lines were isolated from E3.5 blastocysts. TSCs were cultured in the absence of primary MEFs in medium supplemented with FGF4 (RD, 235-F4-025/CF, 30 ng ml<sup>-1</sup>) and heparin (Sigma, H3149, 1.2  $\mu$ g ml<sup>-1</sup>). The medium contained 30 vol% TS medium (RPMI 1640, BD Biosciences, 354230), which includes 20% ES cell-qualified foetal bovine serum (Invitrogen), 1% penicillin-streptomycin (Lonza, DE17-602E), 1% glutamine (Lonza, BE17-605E), 1% sodium pyruvate (Invitrogen, 11360), 0.1 mM  $\beta$ -mercaptoethanol and 70 vol% MEF-conditioned medium (collected from mitomycin C-treated (Sigma, M4287) MEFs cultured in TS medium)<sup>40</sup>. To induce differentiation, TSCs were cultured in TS medium in the absence of FGF4, heparin

and MEF-conditioned medium. *Lsd1* *iKD* and *iKO* TSCs were induced by 1  $\mu$ g ml<sup>-1</sup> doxycyclin (Ratiopharm, 576.00.01) and by 0.2  $\mu$ M 4OH-tamoxifen (Sigma, H-7904), respectively. TSCs were transfected with Lipofectamine LTX according to the manufacturer's instructions (Invitrogen). Puromycin (Sigma, P8833, 1.5  $\mu$ g ml<sup>-1</sup>) was administrated to cells 24 h post transfection. TSCs were transfected with the following miRNA directed against mouse *Ovol2* (5'-TGCTG TTTAGGTGGACTCCAAGGAAGTTTGGCCACTGACTGACTTCCTTGGT CCCACCTAAA-3'; 5'-CCTGTTTAGGTGGACCAAGGAAGTCAGTCAGTG GCCAAAACCTCCTTGGAGTCCACCTAAAC-3') cloned into pRTS. MDA-MB-231 cells were cultured in DMEM (Lonza 12-614Q) with 10% foetal bovine serum (Invitrogen, 10270-106), 1% penicillin-streptomycin and 1% glutamine. For *Lsd1* knockdown<sup>14</sup> cells were seeded at 3  $\times$  10<sup>5</sup> cells in a 10-cm dish and transfected with 25 nM siRNA (final concentration) using Dharmafect 4 (Thermo Scientific).

**In situ analyses.** Embryos at E6.5 to E8.5 were dissected in phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin. Rehydrated 5- $\mu$ m sections were used for HE counterstaining, *in situ* hybridization<sup>41</sup> and immunofluorescence after antigen retrieval<sup>42</sup> using standard protocols. *In situ* hybridization analysis was carried out using a probe for *Ovol2*, which can be requested from the authors. For immunofluorescence,  $\alpha$ -Cdx2 (BioGenex, MU392A-UC, 1:50),  $\alpha$ -Eomes (Abcam, ab23345, 1:200),  $\alpha$ -Lsd1 (no. 3544, 1:200 (ref. 14),  $\alpha$ -Oct4 (Santa Cruz, C-10, 1:50),  $\alpha$ -Vimentin (Sigma, V-2258, 1:100),  $\alpha$ -Cdh1 (BD transduction lab, 610182, 1:100) and  $\alpha$ -Ctnnb1 (BD transduction lab 610154, 1:100) antibodies were used. Specific staining was monitored by hybridization to unrelated mouse (sc-2025), rabbit (sc-2027) and rat (sc-2026) IgG (Santa Cruz) diluted to the same concentration as corresponding primary antibodies. Alexa Fluor-488 goat  $\alpha$ -rabbit IgG and Alexa Fluor 546 goat  $\alpha$ -mouse IgG (Molecular Probes, 1:1,000) were used as secondary antibodies and DAPI (2  $\mu$ g ml<sup>-1</sup>) for counterstaining of nuclei. F-actin was stained with Alexa Fluor-488 Phalloidin (Invitrogen, A12379). Staining was documented with a confocal microscope (Leica SP2AOSB).

**Western blot analysis.** Experiments were performed as described<sup>14</sup>. Briefly, cells were lysed in SC buffer and 30  $\mu$ g of protein extract supernatant was used for western blots. The following antibodies were used:  $\alpha$ -beta Actin (Sigma, A1978, 1:15,000),  $\alpha$ -Cdx2-88 (BioGenex, MU392A-UC, 1:200),  $\alpha$ -Eomes (Abcam, ab23345, 1:1,000),  $\alpha$ -p-ERK1/2 (Cell Signaling, 9101, 1:1,000),  $\alpha$ -ERK1/2 (Cell Signaling, 46951, 1:1,000),  $\alpha$ -H2A (Abcam ab13923, 1:1,000), H2AK5ac (Millipore, 1:1,000),  $\alpha$ -H2B (Santa Cruz, sc-10808, 1:200),  $\alpha$ -H2BK5ac (Robert Schneider, 1:1,000),  $\alpha$ -H3 (Abcam, ab1791, 1:5,000),  $\alpha$ -H3K9ac (Diagenode, pAb-ACHAHS-044, 1:500),  $\alpha$ -Lsd1 (Schüle laboratory 3583, 1:2,000 (ref. 14)),  $\alpha$ -P11 (Santa Cruz, P-17, 1:1,000),  $\alpha$ -p-Smad2 (Cell Signaling, 3101, 1:1,000),  $\alpha$ -Smad2/3 (BD Transduction Lab, 610843, 1:1,000),  $\alpha$ -alpha-tubulin (Sigma, T6074, 1:10,000) and  $\alpha$ -V5 (Invitrogen, R960-25, 1:1,000),  $\alpha$ -Flag M2 (Sigma, F3165, 1:2,500),  $\alpha$ -Ovol2 (Schüle laboratory 8053, 1:1,000). Histones were purified according to the manufacturer's instruction (Active Motif; Histone Purification Kit, 40025). All full-scan western blots are provided in Supplementary Fig. 9.

**Plasmids.** Expression plasmids for *Ovol2*, *Lsd1* and *Lsd1*<sup>Mut</sup> were generated by LR11 recombination according to the supplier (Gateway, Invitrogen) using entry clones (GeneCopoeia; GC-Mm13121-CF; accession number NM\_026924.3; pENTR-Flag-Lsd1, pENTR-Flag-Lsd1<sup>Mut30</sup>, Schüle laboratory) and a puromycin-selectable and doxycyclin-inducible pRTS plasmid<sup>43</sup>, modified to contain a Gateway cassette, V5 and His tags.

**RNA extraction and quantitative RT-PCR.** RNA isolation and quantitative PCR with reverse transcription were performed as described<sup>14</sup>. *Gapdh* was used for normalization and data were related to undifferentiated wild-type TSCs. For normalization of expression in MDA-MB-231 cells, *GAPDH*, *HPR1* and *POLR2A* were used and data were related to cells treated with control siRNA. Experiments were repeated in triplicate three times. Primers are shown in Supplementary Table 5. TaqMan gene expression assay (Life Technologies; no. 4331182) was used to determine *Gcm1* expression.

**Cell culture assays.** Prior to the experiment, *Lsd1* *iKO* and *iKD* TSCs were treated for 8 days with Dox or Tx, respectively. Proliferation assays were performed essentially as described<sup>14</sup> by seeding 3  $\times$  10<sup>3</sup> and 6  $\times$  10<sup>3</sup> cells in 96-well plates in TSC stemness or differentiation culture medium, respectively. The cell proliferation enzyme-linked immunosorbent assay (ELISA) BrdU Colorimetric Assay (Roche) was performed according to the manufacturer's instructions after 24, 48 and 72 h. The experiments were repeated in quadruplicate three times. Cell migration and invasion were monitored using the xCelligence system (Roche). For invasion, transwell chamber filters (Roche) were coated with matrigel (BD Biosciences, 354230) diluted 1:20 in RPMI-1640 medium. *Lsd1* *iKD* or *iKO* TSCs were seeded at 1  $\times$  10<sup>5</sup> cells into transwell in TSC culture medium in the presence or absence of FGF4 and heparin. TSCs were cultured 24 h before and during the experiment in the presence of 10  $\mu$ M *Lsd1* inhibitors substance 1 (2-[(2-{4-[4-fluoro-2-



(trifluoromethyl)phenyl]phenyl]cyclopropyl)amino]-1-(4-methylpiperazin-1-yl)ethan-1-one)<sup>32</sup>, substance 2 (trans-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine)<sup>31</sup>, substance 3 (trans-N-[(2-methoxyppyridin-3-yl)methyl]-2-phenylcyclopropan-1-amine)<sup>31</sup> or DMSO. Cell indices were automatically recorded every 15 min. For visualization, invaded cells were fixed with 4% paraformaldehyde for 5 min on transwell membrane and stained with 0.4% crystal violet for 20 min.

**FACS.** Cell size of TSCs was analysed using the Forward Scatter of the FACScalibur (Becton Dickinson). Data were plotted in a single dimension using the Cell-QuestPro software. For proliferation assays,  $2 \times 10^5$  TSCs were seeded and cultured for 48 h under stemness-maintaining or differentiation conditions. Cell number was determined by addition of AccuCheck counting beads (Invitrogen) to each sample using the FACScalibur for detection.

**cDNA microarray and bioinformatics.** Before the start of the experiment, *Lsd1* iKO TSCs were treated with Tx for 8 days. Cells were harvested before 2 and 4 days after induction of differentiation. RNA was isolated using Trizol (Invitrogen) according to the supplier's protocol, DNaseI-treated (Promega) and quality controlled with 2100 Bioanalyzer (Agilent) analysis. A total of 10  $\mu$ g RNA for each sample was used for reversed transcription. The cDNA was hybridized to GeneChip MG-430\_2.0 arrays (Affymetrix). Expression values were normalized using the RMA algorithm performed with R and Bioconductor software. Further analysis was performed using the Analyst 2.2 software (Genedata, Basel; Switzerland) and DAVID<sup>44,45</sup>. A principal component analysis and hierarchical clustering were used to exclude outliers from further analysis.

**ChIP.** ChIP experiments and quantitative PCR were performed essentially as described<sup>14</sup>. For performing ChIPs, *Lsd1* iKO TSCs were cultured in the presence or absence of Tx and were harvested before and 4 days after induction of differentiation. Cells were washed with PBS and crosslinked with 1% formaldehyde in PBS for 20 min at 4 °C. Cells were then rinsed twice with ice-cold PBS, collected into PBS and centrifuged for 5 min at 2,500 r.p.m. at 4 °C. The pellets were then resuspended in 0.3 ml of lysis buffer (0.1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0 and 1% protease inhibitor cocktail (*Roth*)) and sonicated for 20 min using a Bioruptor (Diagenode; level H, interval on/off: 0.5), followed by centrifugation for 10 min at maximal speed at 4 °C. Supernatants were collected and diluted in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl and 20 mM Tris-HCl, pH 8.0) followed by immunoclearing with 2  $\mu$ g sheared fish sperm DNA and protein A-Sepharose CL-4B (*Amersham Biosciences*) (50  $\mu$ l of 50% slurry in 10 mM Tris-HCl, pH 8.0 and 1 mM EDTA) for 2 h at 4 °C. Immunoprecipitation was performed overnight at 4 °C with specific antibodies (250  $\mu$ g DNA using 5  $\mu$ g antibody). After immunoprecipitation, 50  $\mu$ l protein A-Sepharose and 2  $\mu$ g fish sperm DNA were added, and incubation was continued for another 1 h. Sepharose beads were washed sequentially for 10 min each in TSE I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.0), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl) and Buffer III (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.0). Beads were then washed three times with TE buffer (10 mM Tris-HCl, pH 8.0 and 1 mM EDTA) and extracted with 100  $\mu$ l of 1% SDS, 0.1 M NaHCO<sub>3</sub>. Eluates were pooled and heated at 65 °C overnight to reverse the crosslinking. DNA fragments were purified with a DNA purification kit (QIAquick PCR purification Kit, Qiagen GmbH). For qPCR, 2  $\mu$ l out of 50  $\mu$ l DNA extract were used. qPCR analyses were performed using the LightCycler system (Roche) and Absolute SYBR green ROX Mix (Thermo Scientific). Immunoprecipitations were performed with rbIgG (Diagenode, kch-504-250, lot DW0502),  $\alpha$ -Lsd1 (no. 3544 (ref. 14)),  $\alpha$ -H3K4me1 (Active Motif, 39297, lot21008001),  $\alpha$ -H3K4me2 (Diagenode, CS-035-100, lot A391-001),  $\alpha$ -H3K4me3 (Abcam, ab8580, lot GR33087-1),  $\alpha$ -H3K9me1 (Millipore, 07-450, lot DAM1680820),  $\alpha$ -H3K9me2 (Active Motif, 39753, lot 06710001),  $\alpha$ -H3K9me3 (Millipore, 07-442, DAM1687549),  $\alpha$ -H3K27me3 (Millipore, 07449, lot DAM1514011),  $\alpha$ -PolII (Santa Cruz, N-20, sc-899, lot no. C1413) and  $\alpha$ -H3 (Abcam, ab1791, lot GR15960-2) antibodies on protein A-Sepharose 4B (GE-Healthcare). The primers for quantitative PCR are shown in Supplementary Table 6.

**Statistical analysis.** If not otherwise stated, significance was calculated using an unpaired *t*-test. Data are calculated as mean  $\pm$  s.e.m. or + s.e.m. Experiments were repeated at least three times in triplicate.

## References

- Guzman-Ayala, M., Ben-Haim, N., Beck, S. & Constam, D. B. Nodal protein processing and fibroblast growth factor 4 synergize to maintain a trophoblast stem cell microenvironment. *Proc. Natl Acad. Sci. USA* **101**, 15656–15660 (2004).
- Simmons, D. G. & Cross, J. C. Determinants of trophoblast lineage and cell subtype specification in the mouse placenta. *Dev. Biol.* **284**, 12–24 (2005).
- Arnold, S. J. & Robertson, E. J. Making a commitment: cell lineage allocation and axis patterning in the early mouse embryo. *Nat. Rev. Mol. Cell Biol.* **10**, 91–103 (2009).
- Niwa, H. *et al.* Interaction between Oct3/4 and Cdx2 determines trophoblast differentiation. *Cell* **123**, 917–929 (2005).
- Strumpf, D. *et al.* Cdx2 is required for correct cell fate specification and differentiation of trophoblast in the mouse blastocyst. *Development* **132**, 2093–2102 (2005).
- Russ, A. P. *et al.* Eomesodermin is required for mouse trophoblast development and mesoderm formation. *Nature* **404**, 95–99 (2000).
- Hemberger, M., Hughes, M. & Cross, J. C. Trophoblast stem cells differentiate in vitro into invasive trophoblast giant cells. *Dev. Biol.* **271**, 362–371 (2004).
- Li, M., Liu, G. H. & Izpisua Belmonte, J. C. Navigating the epigenetic landscape of pluripotent stem cells. *Nat. Rev. Mol. Cell Biol.* **13**, 524–535 (2012).
- Kouzarides, T. Chromatin modifications and their function. *Cell* **128**, 693–705 (2007).
- Hemberger, M., Dean, W. & Reik, W. Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington's canal. *Nat. Rev. Mol. Cell Biol.* **10**, 526–537 (2009).
- Hemberger, M. Epigenetic landscape required for placental development. *Cell. Mol. Life Sci.* **64**, 2422–2436 (2007).
- Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. *Nature* **403**, 41–45 (2000).
- Shi, Y. *et al.* Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* **119**, 941–953 (2004).
- Metzger, E. *et al.* LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. *Nature* **437**, 436–439 (2005).
- Metzger, E. *et al.* Phosphorylation of histone H3T6 by PKC $\beta$ (I) controls demethylation at histone H3K4. *Nature* **464**, 792–796 (2010).
- Lee, M. G., Wynder, C., Cooch, N. & Shiekhattar, R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. *Nature* **437**, 432–435 (2005).
- Wang, Y. *et al.* LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. *Cell* **138**, 660–672 (2009).
- Garcia-Bassets, I. *et al.* Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. *Cell* **128**, 505–518 (2007).
- Wang, J. *et al.* The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. *Nat. Genet.* **41**, 125–129 (2009).
- Macfarlan, T. S. *et al.* Endogenous retroviruses and neighboring genes are coordinately repressed by LSD1/KDM1A. *Genes Dev.* **25**, 594–607 (2011).
- Foster, C. T. *et al.* Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability. *Mol. Cell Biol.* **30**, 4851–4863 (2010).
- Wang, J. *et al.* Opposing LSD1 complexes function in developmental gene activation and repression programmes. *Nature* **446**, 882–887 (2007).
- Adamo, A. *et al.* LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. *Nat. Cell Biol.* **13**, 652–659 (2011).
- Whyte, W. A. *et al.* Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. *Nature* **482**, 221–225 (2012).
- Hayashi, S., Lewis, P., Pevny, L. & McMahon, A. P. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. *Mech. Dev.* **119**(Suppl 1): S97–S101 (2002).
- Costello, I. *et al.* The T-box transcription factor Eomesodermin acts upstream of Mesp1 to specify cardiac mesoderm during mouse gastrulation. *Nat. Cell Biol.* **13**, 1084–1091 (2011).
- Nichols, J. *et al.* Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* **95**, 379–391 (1998).
- Arnold, S. J., Sugnaseelan, J., Groszer, M., Srinivas, S. & Robertson, E. J. Generation and analysis of a mouse line harboring GFP in the Eomes/Tbr2 locus. *Genesis* **47**, 775–781 (2009).
- Tanaka, S., Kunath, T., Hadjantonakis, A. K., Nagy, A. & Rossant, J. Promotion of trophoblast stem cell proliferation by FGF4. *Science* **282**, 2072–2075 (1998).
- Lee, M. G. *et al.* Functional interplay between histone demethylase and deacetylase enzymes. *Mol. Cell Biol.* **26**, 6395–6402 (2006).
- Harris, W. J. *et al.* The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. *Cancer Cell* **21**, 473–487 (2012).
- Ueda, R. *et al.* Identification of cell-active lysine specific demethylase 1-selective inhibitors. *J. Am. Chem. Soc.* **131**, 17536–17537 (2009).
- Unezaki, S., Horai, R., Sudo, K., Iwakura, Y. & Ito, S. *Ovol2/Movo*, a homologue of *Drosophila ovo*, is required for angiogenesis, heart formation and placental development in mice. *Genes Cells* **12**, 773–785 (2007).
- Mackay, D. R., Hu, M., Li, B., Rheaume, C. & Dai, X. The mouse *Ovol2* gene is required for cranial neural tube development. *Dev. Biol.* **291**, 38–52 (2006).
- Abell, A. N. *et al.* MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. *Cell Stem Cell* **8**, 525–537 (2011).

36. Lin, T., Ponn, A., Hu, X., Law, B. K. & Lu, J. Requirement of the histone demethylase LSD1 in Snail-mediated transcriptional repression during epithelial-mesenchymal transition. *Oncogene* **29**, 4896–4904 (2010).
37. Lin, Y. *et al.* The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. *EMBO J.* **29**, 1803–1816 (2010).
38. McDonald, O. G., Wu, H., Timp, W., Doi, A. & Feinberg, A. P. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. *Nat. Struct. Mol. Biol.* **18**, 867–874 (2011).
39. Seibler, J. *et al.* Single copy shRNA configuration for ubiquitous gene knockdown in mice. *Nucleic Acids Res.* **33**, e67 (2005).
40. Quinn, J., Kunath, T. & Rossant, J. Mouse trophoblast stem cells. *Methods Mol. Med.* **121**, 125–148 (2006).
41. Nagy, A., Gertsenstein, M., Vintersten, K. & Behringer, R. *Manipulating the Mouse Embryo: A Laboratory Manual* 3rd edn (CSH Press, 2002).
42. Müller, J. M. *et al.* FHL2, a novel tissue-specific coactivator of the androgen receptor. *EMBO J.* **19**, 359–369 (2000).
43. Hölzel, M. *et al.* Rapid conditional knock-down-knock-in system for mammalian cells. *Nucleic Acids Res.* **35**, e17 (2007).
44. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57 (2009).
45. Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* **37**, 1–13 (2009).

### Acknowledgements

We thank Georg Bornkamm (GSF Research Centre, Munich) for providing the pRTS plasmid, Nora Hagemeyer and Katrin Kierdorf for FACS analyses, Ludger Klein-Hitpass (BioChip-Laboratory; University Clinic Essen, Germany) for supplying RNA expression data, Robert Schneider (IGBMC, Strasbourg, France) for the H2BK5ac antibody and

Elmar Stickeler (Womens Hospital, University Medical Centre Freiburg) for MDA-MB-231 cells. We are obliged to Vanessa Rüsseler, Dorothea Hassan, Joachim Lauterwasser and Astrid Rieder for providing excellent technical assistance, and we thank Mary Follow, Holger Greschik, Michael Kötting and Judith M. Müller for critical reading of the manuscript. This work was supported by the European Research Council (ERC), German Research Council (DFG) and the Else Kröner-Fresenius-Stiftung, Emmy Noether Programme AR 732/1-1 and SFB850 to S.J.A., GU 598/1-3 and 2012\_A72 to T.G., and ERC AdG 322844, SFB992, SFB850, SFB746, Schu 688/9-1, Schu 688/11-1 and Schu 688/12-1 to R.S.

### Author contributions

D.Z., S.H., T.G., S.J.A. and R.S. designed the experiments, D.Z., S.H., E.M., M.P., A.J., C.J., P.G., C.H., M.M., D.M. and S.J.A. performed research, D.Z., S.H., E.M., T.G., S.J.A. and R.S. analysed the data, T.G., S.J.A. and R.S. wrote and edited the manuscript.

### Additional information

**Accession codes:** All microarray data are deposited at the GEO database repository under accession number GSE38277.

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Zhu, D. *et al.* Lysine-specific demethylase 1 regulates differentiation onset and migration of trophoblast stem cells. *Nat. Commun.* 5:3174 doi: 10.1038/ncomms4174 (2014).